Essure: Permanent Contraception Device Risks and Oversight

The claim and its context

Essure was a hysteroscopic permanent-contraception device. Patients reported pain, bleeding, perforation, migration, and device removal; regulators added warnings and required a patient decision checklist. The existence of real complications does not show that every report was caused by the device or that the FDA concealed a known universal danger.

Historical chronology

FDA approved Essure in 2002 through the premarket approval pathway. As postmarket reports accumulated, the FDA required additional studies, a boxed warning, and a checklist in 2016. Bayer stopped new U.S. sales at the end of 2018. FDA-required follow-up and safety monitoring continued for those with implants.

What the record establishes

FDA adverse-event reports and comparative studies identify complications, including persistent pain and repeat procedures. These data are important safety signals but have limitations: passive reports can be incomplete, duplicated, and lack a comparison group. The FDA’s post-approval study and registry-based comparisons offer stronger estimates for defined outcomes.

Clinical and scientific context

Essure inserts were placed through the uterus into the fallopian tubes; permanent contraception depends on appropriate placement and tissue response. Risks must be compared with alternative sterilization procedures and with the consequences of unintended pregnancy. Discontinuing sales does not remove existing devices or establish a one-size-fits-all clinical response.

Counterevidence, uncertainty, and calibration

Study estimates vary by outcome definition, follow-up, and comparator. Some complaints reported after implantation may have unrelated causes, while passive systems can undercount harms. The balanced conclusion is that device-specific complications prompted meaningful regulatory action; blanket claims that every implant is dangerous or that no genuine risk existed are both unsupported.

What could change the assessment

Long-term, complete outcome data linked to device and comparator records could improve estimates of pain, reoperation, and removal. Independent analysis of adverse-event reports and clinical records could resolve disputed counts and causation.

Source notes and limitations

1. FDA — Essure Permanent Birth ControlRegulatory timeline, boxed warning, checklist, and current postmarket information; agency action is not proof that each reported event was caused by Essure.
2. FDA — 522 Postmarket Surveillance Studies Database: EssureRequired postmarket-study records for outcome follow-up; study design and attrition affect interpretation.
3. Mao et al. — Safety and Efficacy of Hysteroscopic Sterilization Compared with Laparoscopic Sterilization, BMJ (2015)Comparative observational study using insurance data; residual confounding and coding limitations remain.